Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Ovarian Neoplasms 7Neoplasms 5Breast Neoplasms 3Recurrence 2Hypersensitivity 2Fallopian Tube Neoplasms 2Uterine Neoplasms 1Stomach Neoplasms 1Solid Tumor 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Prostatic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Neoplasms, Unknown Primary 1Neoadjuvant Therapy 1Lung Neoplasms 1Kenny-Caffey syndrome, Type 1 1Gastrointestinal Stromal Tumors 1Gastrointestinal Neoplasms 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1Colorectal Neoplasms 1Biliary Tract Neoplasms 1Adenocarcinoma 1

Interventions

Carboplatin 346Cisplatin 240Paclitaxel 208Radiotherapy 207Pemetrexed 190Docetaxel 170Gemcitabine 158pembrolizumab 147Erlotinib Hydrochloride 111Magnetic Resonance Spectroscopy 102Etoposide 99Bevacizumab 96Specimen Handling 84Nivolumab 77Radiosurgery 74durvalumab 73Blood Specimen Collection 65Drug Therapy 61osimertinib 56Vinorelbine 54Gefitinib 50Surveys and Questionnaires 48atezolizumab 45Biopsy 43Radiation 42Irinotecan 42Topotecan 39Standard of Care 39Cyclophosphamide 38Surgical Procedures, Operative 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × Poly(ADP-ribose) Polymerase Inhibitors × Clear all
NCT05392686 2022-05-26

PD1 and PARP for Maintenance Therapy in NSLLC

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Unknown
52 enrolled
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡